NeuroTherapia, Inc.

Neuro Therapia, founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is a health care and pharmaceutical startup focused on developing therapies for diseases with a neuroinflammatory component. The company's lead compound NTRX-07 shows promising results in decreasing activation of microglial cells in the brain, leading to reduced inflammation and nerve cell injury, with potential applications in treating neuropathic pain and Alzheimer's Disease. The recent $8.80M Series A investment, led by Brain Trust Accelerator Fund, Dolby Ventures, Cleveland Clinic, and the Alzheimer's Drug Discovery Foundation, indicates strong support for Neuro Therapia's innovative approach. With an experienced leadership team including CEO Tony Giordano, Ph.D. and VP of Research and Development Marianna Kiraly, Ph.D., the company is well-positioned to advance its promising therapies through Phase 2 trials and potentially make a significant impact in the field of neuroinflammation research and treatment.